Categories: News

AIM Vaccine submitted the pre-application for clinical trials for novel-process highly-effective human diploid rabies vaccine

Achieve quality upgrade of traditional human diploid wild seedlings

HONG KONG SAR – Media OutReach Newswire – 27 March 2024 – AIM Vaccine Co., Ltd. (the “AIM Vaccine”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has submitted the pre-application for clinical trials for novel-process highly-effective human diploid rabies vaccine on March 24, 2024.

Currently, there is a lack of effective clinical treatment for rabies, and therefore post exposure prevention is crucial. The main preventive measures are inoculation of human rabies vaccine and injection of passive immunization agents. The human diploid cell rabies vaccine has natural safety advantages and a broad market space. This time AIM Vaccine submitted a pre-application for clinical trials for novel-process highly-effective human diploid rabies vaccine, which is a major breakthrough.

The novel-process highly-effective human diploid rabies vaccine developed by AIM Vaccine became the first to break through the technical bottleneck of low virus titer and small yield in the traditional process, with optimized and innovated purification process, which has notably improved product quality and safety as compared with similar marketed products in China, and has the production capacity for large-scale commercialization.
Hashtag: #AIMVaccine

The issuer is solely responsible for the content of this announcement.

About AIM Vaccine Co., Ltd.

AIM Vaccine (stock code: 06660) is committed to manufacturing conscientious vaccines and promoting the health of the people. It is the second-largest vaccine group in China and the largest private-sector vaccine group, with a complete industry chain. AIM Vaccine is a leading company in the Chinese vaccine industry and one of the top players in the mRNA vaccine field. As one of the most strictly regulated industries in the country, China has over 40 vaccine production qualifications nationwide. Currently, AIM Vaccine owns four wholly-owned licensed vaccine production companies and three vaccine research institutes. It is one of the only two human vaccine companies in China with strategic resources such as P3 laboratories. AIM Vaccine is also the world’s largest manufacturer of hepatitis B vaccines and the second-largest manufacturer of rabies vaccines globally.

AIM Vaccine has a portfolio of 8 commercialized vaccines and 23 vaccines under development, covering the top ten vaccine varieties globally. Its commercialized products have maintained a leading market position for a long time, with sales covering all 31 provinces, municipalities, and autonomous regions in China, reaching over 2,000 district and county-level disease control centers.

Miscw.com

Recent Posts

“One Earth Summit” 2025 Held Successfully Hong Kong Fully Leverages Its Role as an International Financial Center and Leader in Green Finance

Laying a Solid Foundation for the Development of ESG Investment and Green Innovation Calling for…

2 days ago

The Campaign “It’s Time for EU Beef” is coming to Cebu and Manila in April

The Philippine meat industry will be shown the quality and guarantees of European beef MANILA,…

2 days ago

European beef will continue to play aleading role in Singapore in the coming months of 2025

"It’s Time for European Beef" is a campaign led by Provacuno and co-funded by the…

2 days ago

Make Waves at Galaxy Macau: Dive into a Luxurious One-Stop Ultimate Holiday Escape with the Reopening of the Grand Resort Deck

MACAU SAR - Media OutReach Newswire - 27 March 2025 - The world-class luxurious Galaxy…

2 days ago

Diabetes Association Unveils T-CaReMe Taipei Declaration at the Asia Diabetes International Conference

In an effort to achieve a target of 80% of patients controlling the three highs…

2 days ago

Li Ning Company Limited Announces 2024 Annual Results

Strengthen the “Single Brand, Multi-Categories, Diversified Channels” Strategy | Solidify Brand and Product Competitiveness, Ensure…

2 days ago